Sun Pharma launches cough syrup Chericof 12 in India

October 6, 2021 Gubba Pharma In E News

Sun Pharmaceutical Industries Ltd. on Tuesday, September 28, 2021, announced the launch of a novel formulation in cough management – Chericof 12 (Dextromethorphan Hydrobromide 30 mg and Chlorpheniramine Maleate 4 mg) in India. Chericof 12, the first prescription cough syrup in India which gives relief for up to 12 hours, is manufactured using Polistirex technology for sustained release of the drug. Chericof 12 is approved for patients of age group six years and above. All cough syrups generally give relief for 6-8 hours, and hence a patient has to take it three to four times a day. Frequent dosing often leads to patient inconvenience and non-adherence to follow the regimen, which may compromise the efficacy of the medication and disturb the daily lifestyle. The Polistirex technology used in Chericof 12 provides sustained release of the medicine in the body, thus offering up to 12-hour relief to patients with twice-daily dosage.
Kirti Ganorkar, CEO – India Business, Sun Pharma said “At Sun Pharma, we always endeavour to introduce differentiated medicines that enhance convenience or solve patients’ problems, thus helping them to cope better with their ailments. The Polistirex technology used in Chericof 12 helps in improving patient compliance and avoids the need for frequent dosing.” Polistirex Technology involves the complexation of two drugs, Dextromethorphan Hydrobromide and Chlorpheniramine maleate with resins. The resin granules of both drugs are added in suspension to form Chericof 12. Complexation of drugs with polistirex not only provides sustained release but also masks the bitter taste making it more palatable. The company in a statement has said that Chericof 12 is a prescription product and should only be taken on the doctor’s advice.

Source: thehansindia

Gubba Group

About the author

Gubba Group: